You are here

A2a--Adenosine Agonist for Cardiovascular Imaging

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 HL55064-01,
Agency Tracking Number: 29562
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2028 Dabney Road, E-17
Richmond, VA 23230
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Pauline Martin
 () -
Business Contact
Phone: () -
Research Institution

Adenosine produces coronary vasodilation through activation of A-2a adenosine receptors. However adalso acts at A1 adenosine receptors to slow atrioventricular conduction and when injected into man ican be blocked with A1 receptor antagonists. DTI has synthesized a number of adenosine analogs that2a subtype of adenosine receptor and have identified WRC-0470 as a potent selective short acting corour belief that WRC- 0470 will prove to be superior to currently available pharmacological stress agbe a useful diagnostic aid in myocardial imaging techniques. We will i) develop synthetic chemical pefficient scale up of bulk material, ii) determine the stability of the compound in a variety of solvehicle for use as an injectable drug, iii) determine the safety and the optimal mode of administratconscious dog model in which coronary vasodilation and other cardiovascular parameters may be measurPhase II will support manufacture of clinical trials supplies, toxicology, and Phase I and Phase II

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government